EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis

Hermine I Brunner iD, Ellen M Cody, Prasad Devarajan, Bin Huang iD, Chen Chen, Dominic Sinibaldi, Madhu Ramaswamy, Jacob Knagenhjelm, Frederick Jones, Philip Z Brohawn, Raj Tummala, Catharina Lindholm iD und 1 weitere

Arthritis Care & Research · 2026-06 · 78 (6) · 723-732

DOI: 10.1002/acr.25684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 23.02.2026. Verfasst von Hermine I Brunner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic, Kidney. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, Marianne and Ralph Falk Medical Trust; NIAMS Core Center, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We evaluated the ability of the Renal Activity Index for Lupus (RAIL) to discriminate active lupus nephritis (LN) in adult patients with active systemic lupus erythematosus (SLE) and differentiate LN treatment response.

Methods

Urine samples from adults with biopsy‐proven active class III and IV LN from TULIP‐LN (active LN group; ClinicalTrials.gov identifier: NCT02547922) and adults with active, nonrenal SLE from TULIP‐1 (active SLE group; ClinicalTrials.gov identifier: NCT02446912) were used, and RAIL biomarkers (neutrophil gelatinase–associated lipocalin, kidney injury molecule 1, monocyte chemotactic protein 1, adiponectin, hemopexin, and ceruloplasmin) were measured in the urine at baseline for both studies and at weeks 12 and 24 for TULIP‐LN only. The groups were compared at baseline, and changes in RAIL scores from baseline in the active LN group were compared between nonresponders and responders over time, ie, those with complete renal response (CRR), partial renal response (PRR), and urine protein–creatine ratio decrease ≥50% (UPCR50).

Results

At baseline, median (interquartile range [IQR]) concentrations of RAIL biomarkers were significantly higher ( P ≤ 0.02) in the active LN group (n = 128) versus the SLE control group (n = 48), as were RAIL scores (5.59 [IQR 4.31–6.47] vs 3.57 [IQR 2.78–4.47]; P < 0.001). At weeks 12 and 24, there were 25 and 31 patients with CRR, 39 and 54 patients with PRR, and 41 and 63 patients with UPCR50, respectively. Changes in RAIL scores from baseline to weeks 12 and 24 significantly differed between nonresponders and responders (PRR, CRR, UPCR50: all P < 0.0006), with lower scores in responders. For CRR versus non‐response, median [IQR] RAIL scores decreased by −1.3 (−3.64 to −0.21) versus −0.39 at week 12, and −2.30 (−3.63 to −1.03) versus −0.88 (−2.20 to 0.33) at week 24, respectively.

Conclusions

The RAIL identifies active LN and longitudinally differentiates treatment response in adults with LN. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisLupus Erythematosus, SystemicKidneyHumansAdultFemaleMaleBiomarkersMiddle AgedTreatment OutcomeSeverity of Illness IndexYoung Adult

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Medical College of Wisconsin, Milwaukee.
  • AstraZeneca, Gaithersburg, Maryland.
  • AstraZeneca, Gothenburg, Sweden.
  • AstraZeneca, Cambridge, United Kingdom.

ORCID-Profile: Hermine I Brunner, Bin Huang, Catharina Lindholm

Förderung

  • NIAMS NIH HHS
  • Marianne and Ralph Falk Medical Trust; NIAMS Core Center
  • AstraZeneca

Zitieren

APA

Brunner, H. I., Cody, E. M., Devarajan, P., Huang, B., Chen, C., Sinibaldi, D., Ramaswamy, M., Knagenhjelm, J., Jones, F., Brohawn, P. Z., Tummala, R., Lindholm, C., & White, W. I. (2026). The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis Care & Research, 78(6), 723-732. https://doi.org/10.1002/acr.25684

Vancouver

Brunner HI, Cody EM, Devarajan P, Huang B, Chen C, Sinibaldi D, et al. The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis Care & Research. 2026;78(6):723-732. doi:10.1002/acr.25684

BibTeX
@article{Brunner2026,
  author = {Brunner, Hermine I and Cody, Ellen M and Devarajan, Prasad and Huang, Bin and Chen, Chen and Sinibaldi, Dominic and Ramaswamy, Madhu and Knagenhjelm, Jacob and Jones, Frederick and Brohawn, Philip Z and Tummala, Raj and Lindholm, Catharina and White, Wendy I},
  title = {The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis},
  journal = {Arthritis Care & Research},
  year = {2026},
  volume = {78},
  number = {6},
  pages = {723--732},
  doi = {10.1002/acr.25684}
}
Kostenlos starten →